Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmacokinetics genetic polymorphism

Wang, J. H., Liu, Z. Q., Wang, W. etal. (2001). Pharmacokinetics of sertraline in relation to genetic polymorphism ofCYP2C19. Clin. Pharmacol. Ther., 70, 42-7. [Pg.85]

Si, T. M., Yang, Q., Liu, Y. et al. (2006). The relationship between the genetic polymorphism ofCYP P450 2C19 and the pharmacokinetics of escitalopram in Chinese volunteers. Chinese Journal of New Drugs, 15(15), 1296-9. [Pg.95]

Desta, Z., Zhao, X., Shin, J.G., and Elockhart, D.A. (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958. [Pg.31]

Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., et al. (2004) Effect of genetic polymorphism of OATP-C (SLCOIBI) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375-380. [Pg.62]

Bosch, T.M., Meijerman, I., Beijnen, J.H., et al. (2006) Genetic polymorphisms of drug-metabolising enzymes and drag transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet. 45, 253-285. [Pg.72]

HesseUnk, D. A., Van Gelder, T., Van Schaik, R. H., et al. (2004) Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin. Pharmacol. Ther. 76, 545-556. [Pg.411]

Eukasawa, T., Suzuki, A. and Otani, K. (2007) Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. Journal of Clinical Pharmacy and Therapeutics, 32, 333—341. [Pg.67]

If the enzyme is subject to genetic polymorphism with an allele coding for a nonfunctional enzyme, the comparison of the pharmacokinetics of a dmg in subjects homozygous for the null allele to control subjects can yield a value for L-... [Pg.185]

It has to be realized that adrenergic receptor sensitivity as well as the pharmacokinetics of the compounds that interact with these receptors are under genetic control. Genetic polymorphism of the metabolism of e.g. propranolol is of clinical importance as is probably also the sensitivity for e.g. P2 mimetic s. [Pg.308]

Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs clinical relevance. Clin Pharmacokinet 2005 44(12) 1209-25. [Pg.473]

Ma, J.D., A.N. Nafziger, and J.S. Bertino, Jr. 2004. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol 44 447. [Pg.28]

Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003 58 809-812. [Pg.143]

Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003 13 619-626. [Pg.204]

See other pages where Pharmacokinetics genetic polymorphism is mentioned: [Pg.88]    [Pg.88]    [Pg.88]    [Pg.88]    [Pg.893]    [Pg.923]    [Pg.948]    [Pg.58]    [Pg.3]    [Pg.163]    [Pg.192]    [Pg.220]    [Pg.491]    [Pg.565]    [Pg.254]    [Pg.256]    [Pg.23]    [Pg.60]    [Pg.61]    [Pg.411]    [Pg.207]    [Pg.435]    [Pg.442]    [Pg.527]    [Pg.531]    [Pg.107]    [Pg.138]    [Pg.22]    [Pg.37]    [Pg.172]    [Pg.444]    [Pg.145]   
See also in sourсe #XX -- [ Pg.207 ]



SEARCH



Genetics polymorphism

© 2024 chempedia.info